5 Results for "

IGROV1

" in MedChemExpress (MCE) Product Catalog:
Products (5)

5 Results for "IGROV1" in MCE Product Catalog:

Cat. No.: HY-148194
CAS No.: 1977557-97-3
Purity:  99.97%
Research Areas:  

Cancer

SC239 is a cleavable 2-aminophenyl hemiasterlin agent-linker. SC239 can be as the agent-linker for ADC [1]. SC239 is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
loading...
    loading...
Cat. No.: HY-175428
CAS No.: 518063-75-7
Target:  

Antifolate

Research Areas:  

Cancer

Antifolate agent 1 is a 6-substituted pyrrolopyrimidine antifolate with a 1-carbon bridge. Antifolate agent 1 shows no activity against cells expressing FRα and FRβ, and has no GARFTase inhibitory activity. Antifolate agent 1 can be used as a negative control in the development of folate receptor-targeted antifolates [1].
loading...
    loading...
Cat. No.: HY-P11011
CAS No.: 2232233-39-3
Synonyms: Pep R54; CXCR4 antagonist peptide 19
Target:  

CXCR ERK Akt

Research Areas:  

Cancer

Peptide R54 (Pep R54) is a CXCR4 antagonist. Peptide R54 inhibits CXCL12-dependent activation of pERK1/2 and pAKT. The combination of Peptide R54 and Nivolumab (HY-P9903) suppresses melanoma growth. Peptide R54 (acetate) is applicable to research related to melanoma and ovarian cancer [1] .
loading...
    loading...
Cat. No.: HY-P11011A
Synonyms: Pep R54 acetate; CXCR4 antagonist peptide 19 acetate
Target:  

CXCR ERK Akt

Research Areas:  

Cancer

Peptide R54 acetate (Pep R54 acetate) is a CXCR4 antagonist. Peptide R54 acetate inhibits CXCL12-dependent activation of pERK1/2 and pAKT. The combination of Peptide R54 acetate and Nivolumab (HY-P9903) suppresses melanoma growth. Peptide R54 (acetate) is applicable to research related to melanoma and ovarian cancer [1] .
loading...
    loading...
Cat. No.: HY-P992004
Synonyms: RA15-7, HuRA15-7Acc

Target:  

Folate Receptor (FR)

Research Areas:  

Cancer

KHK2805 (RA15-7) is a humanized antibody against folate receptor α (FOLR1), with a Kd of 0.647 nM for human FOLR1. KHK2805 binds to a unique epitope of FOLR1 and mediates antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity against FOLR1-expressing cells. KHK2805 exhibits cytotoxicity against both ovarian cancer cells and Platinum (HY-W096169D)-resistant ovarian cancer cells. KHK2805 can be used for the research of tumors such as ovarian cancer [1].
loading...
    loading...